BridgeBio Pharma Inc reports results for the quarter ended December 31 - Earnings Summary

• BridgeBio Pharma Inc BBIO.OQ reported a quarterly adjusted loss of $1.40​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -96 cents. The mean expectation of fifteen analysts for the quarter was for a loss of $1.13 per share. Wall Street expected results to range from $-1.46 to -90 cents per share.

• Revenue rose 237.1% to $5.88 million from a year ago; analysts expected $3.48 million.

• BridgeBio Pharma Inc's reported EPS for the quarter was a loss of $1.40​.

• The company reported a quarterly loss of $265.05 million.

• BridgeBio Pharma Inc shares had risen by 32.3% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.8% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for BridgeBio Pharma Inc is $49.00

This summary was machine generated from LSEG data February 20 at 02:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)